BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Sell Rating, Announces Target Price $155

Futu NewsJan 6 19:31 · Ratings

SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?

Seeking AlphaJan 6 06:32

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Madrigal PharmaceuticalsJan 3 13:00

VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?

Zacks Jan 2 18:30

Leerink Partners Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390

Futu NewsDec 18, 2024 14:31 · Ratings

Sagimet Started at Outperform by Oppenheimer, MASH Drug Cited

Seeking AlphaDec 7, 2024 02:56